Companies › Praxis Precision Medicines
6 active drug programs in 7 registered trials: 4 Phase 3, 2 Phase 2, 1 Phase 1; Neurology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| elsunersen antisense oligonucleotide targeting SCN2A | Ion channels | Phase 3 | Epileptic Encephalopathy | Dec 2026 |
| relutrigine (PRAX-562) NMDA receptor antagonist; selective GluN2B-containing NMDA receptor inhibitor | GRIN2B | Phase 3 | Developmental and Epileptic Encephalopathy 1; SCN2A Encephalopathy | Dec 2026 |
| vormatrigine Sodium channel modulator | – | Phase 3 | Focal Epilepsy | Jan 2027 |
| ulixacaltamide NMDA receptor antagonist (GluN2B subunit selective) | GRIN2B | Phase 3 | Essential Tremor | Mar 2027 |
| PRAX-628 | – | Phase 2 | Focal Onset Seizure | – |
| PRAX-222 Selective sodium channel modulator targeting SCN2A mutations | Ion channels | Phase 1 | SCN2A-DEE | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06908356 | PRAX-628 | Phase 2 | Focal Onset Seizure | Neurology | Jul 2025 |
| NCT07010471 | relutrigine (PRAX-562) | Phase 3 | Developmental and Epileptic Encephalopathy 1 | Neurology | Dec 2026 |
| NCT07019922 | elsunersen | Phase 3 | Epileptic Encephalopathy | Neurology | Dec 2026 |
| NCT07505004 | vormatrigine | Phase 3 | Focal Epilepsy | Neurology | Jan 2027 |
| NCT05818553 | relutrigine (PRAX-562) | Phase 2 | SCN2A Encephalopathy | Neurology | Mar 2027 |
| NCT06087276 | ulixacaltamide | Phase 3 | Essential Tremor | Neurology | Mar 2027 |
| NCT05737784 | PRAX-222 | Phase 1 | SCN2A-DEE | Neurology | Feb 2028 |
Cash and short-term investments of $1.3bn on 2026-09-30; operating cash outflow about $329m a year; runway about 47 months at that burn, to Sep 2030; 5 of 5 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Actio Biosciences Aptinyx SHINKEI Therapeutics Xenon Pharmaceuticals Ionis Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.